Data from Aggarwal and colleagues resulting from testing of the combination of the HDAC inhibitor abexinostat and pazopanib [30] in a phase I trial of patients with solid tumors were challenging, as the first clinical evidence of an epigenetic modulation by using HDAC inhibition to reverse tumor resistance to VEGF inhibitors was shown. This evidence concerns the gene HDAC9 and neoplasm.